Marks Group Wealth Management Inc Has $1.62 Million Stake in Cencora, Inc. $COR

Marks Group Wealth Management Inc raised its position in Cencora, Inc. (NYSE:COR) by 620.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,782 shares of the company’s stock after purchasing an additional 4,118 shares during the period. Marks Group Wealth Management Inc’s holdings in Cencora were worth $1,615,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Oakworth Capital Inc. acquired a new position in shares of Cencora in the 4th quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new position in shares of Cencora in the 4th quarter worth approximately $27,000. Archer Investment Corp lifted its position in shares of Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the period. Optima Capital LLC acquired a new position in shares of Cencora during the 4th quarter valued at $31,000. Finally, Basepoint Wealth LLC acquired a new position in shares of Cencora during the 4th quarter valued at $32,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. William Blair assumed coverage on shares of Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. UBS Group boosted their target price on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley set a $342.00 target price on shares of Cencora in a research report on Friday, May 8th. Evercore set a $360.00 target price on shares of Cencora in a research report on Wednesday, April 8th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $380.25.

Cencora Stock Performance

Shares of COR stock opened at $279.15 on Wednesday. The firm has a market capitalization of $54.31 billion, a PE ratio of 21.41, a price-to-earnings-growth ratio of 1.48 and a beta of 0.59. The firm has a fifty day simple moving average of $291.16 and a two-hundred day simple moving average of $329.11. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts forecast that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is 18.40%.

Cencora announced that its Board of Directors has approved a share buyback plan on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.